[Clinical analysis of 32 cases with neuroendocrine carcinoma of the uterine cervix in early-stage disease]
- PMID: 26268410
[Clinical analysis of 32 cases with neuroendocrine carcinoma of the uterine cervix in early-stage disease]
Abstract
Objective: To investigate the survival and recurrence data after treatment in neuroendocrine carcinoma of the uterine cervix (NECUC) with stage Ib-IIa, and to analyse its prognostic factors.
Methods: Thirty-two cases of primary NECUC in early-stage disease treated from Jan. 2005 to Dec. 2013 at Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences were reviewed, and their data of clinicopathologic characteristics were collected and analysed. The median age was 37 years (range, 23-57 years). The distribution by International Federation of Gynecology and Obstetrics (FIGO) clinical stage: 19 cases stage Ib1, 10 cases stage Ib2, 1 case stage IIa1, 2 cases stage IIa2. Pathologic types: 22 cases of small cell carcinoma, 1 case of atypical carcinoid, 9 cases of mixed carcinoma. The diameter of cervical tumor: 12 cases ≥4 cm, 20 cases <4 cm. All patients underwent radical hysterectomy and pelvic ± para-aortic lymphadenectomy, and 15 cases of them were preserved unilateral or bilateral ovaries. Pathologic examination showed that 25 cases with cervical deep stromal invasion thickness ≥1/2, 21 cases with lymph-vascular space invasion (LVSI), and 18 cases with pelvic and (or) para-aortic lymph nodes involvement. Ten cases were performed neoadjuvant chemotherapy (range,1-3 cycles), all patients received postoperative chemotherapy (range,3-6 cycles), and 15 patients were treated with radiotherapy after surgery. The follow-up data were updated on Jul. 2014. The median follow-up time was 18 months (range, 7-71 months). A retrospective analysis was conducted to analyse the survival and recurrence data,and to explore the prognostic factors of NECUC.
Results: Thirteen patients died during the follow-up period. The cumulative progression-free survival (PFS) of 2 and 5 years were respectively 54.2% and 38.1%, and the estimated median PFS was 29 months. The cumulative overall survival (OS) of 2 and 5 years were respectively 56.1% and 44.9%, and the estimated median OS was 31 months. Fourteen cases had recurrence, and the median recurrence time was 9 months (range, 3-30 months). Recurrent or metastatic sites: 2 cases in pelvis, 4 cases in liver, 3 cases in lung, 3 cases in adrenal glands, 3 cases in bones, 2 cases in brain, 1 case in pancreas, 1 case in lymph nodes of para-aorta and neck, and 3 cases had metastasis in two or more organs. Thirteen cases with recurrence died of disease, and another one is alive with disease. The univariate analysis showed that lesion size of the cervix and FIGO stage were significant prognostic factors (P<0.01), while age, tumor components, deep invasion in cervical stromal, LVSI, pelvic and (or) para-aortic lymph nodes involvement, neoadjuvant chemotherapy, adjuvant radiotherapy and preserving ovaries were not significantly associated with prognosis (all P>0.05).
Conclusion: The prognosis of NECUC in early-stage is poor and the lesion size of the cervix and FIGO stage are prognostic factors.
Similar articles
-
[Neuroendocrine carcinoma of cervix: a clinicopathologic study of 82 cases].Zhonghua Bing Li Xue Za Zhi. 2018 May 8;47(5):328-333. doi: 10.3760/cma.j.issn.0529-5807.2018.05.003. Zhonghua Bing Li Xue Za Zhi. 2018. PMID: 29783797 Chinese.
-
[Long-term oncological outcomes after laparoscopic versus abdominal radical hysterectomy in stage I a2- II a2 cervical cancer: a matched cohort study].Zhonghua Fu Chan Ke Za Zhi. 2015 Dec;50(12):894-901. Zhonghua Fu Chan Ke Za Zhi. 2015. PMID: 26887872 Chinese.
-
Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study.Ann Oncol. 2008 Feb;19(2):321-6. doi: 10.1093/annonc/mdm465. Epub 2007 Oct 24. Ann Oncol. 2008. PMID: 17962205
-
Can laparoscopic radical hysterectomy be a standard surgical modality in stage IA2-IIA cervical cancer?Gynecol Oncol. 2012 Oct;127(1):102-6. doi: 10.1016/j.ygyno.2012.06.003. Epub 2012 Jun 7. Gynecol Oncol. 2012. PMID: 22683586 Review.
-
[Caring for stage IB cancer of the cervix. Proposal for a protocol based on a review of the literature].Gynecol Obstet Fertil. 2003 Jan;31(1):2-13. doi: 10.1016/s1297-9589(02)00002-4. Gynecol Obstet Fertil. 2003. PMID: 12659779 Review. French.
Cited by
-
Amphricrine carcinoma of the cervix-adeno neuroendocrine tumor: A case report.Turk J Obstet Gynecol. 2016 Jun;13(2):99-102. doi: 10.4274/tjod.72325. Epub 2016 Jun 15. Turk J Obstet Gynecol. 2016. PMID: 28913101 Free PMC article.
-
Clinicopathological Analysis of Neuroendocrine Carcinoma of the Uterine Cervix: A Single-Institution Retrospective Review of 9 Cases.Int J Surg Oncol. 2021 Sep 16;2021:8290659. doi: 10.1155/2021/8290659. eCollection 2021. Int J Surg Oncol. 2021. PMID: 34567803 Free PMC article.
-
Neuroendocrine carcinoma of the cervix: a systematic review of the literature.BMC Cancer. 2018 May 4;18(1):530. doi: 10.1186/s12885-018-4447-x. BMC Cancer. 2018. PMID: 29728073 Free PMC article.
-
Small cell carcinoma of the cervix complicated by syndrome of inappropriate antidiuretic hormone secretion: a case report.J Int Med Res. 2021 Feb;49(2):300060520985657. doi: 10.1177/0300060520985657. J Int Med Res. 2021. PMID: 33596689 Free PMC article.
-
Prognostic model for survival in patients with neuroendocrine carcinomas of the cervix: SEER database analysis and a single-center retrospective study.PLoS One. 2024 Jan 5;19(1):e0296446. doi: 10.1371/journal.pone.0296446. eCollection 2024. PLoS One. 2024. PMID: 38181016 Free PMC article.